Preptin and Myostatin Independently Increase in Pre-Diabetics and Patients of Type 2 Diabetes Mellitus

Abstract

Abstract- The relation between serum preptin, myostatin, insulin, and also homeostatic model assessmentinsulin resistance were examined in pre-diabetes persons and newly diagnosed patients with overt type 2 diabetes mellitus. A total of 84 subjects were included in the study and assigned into three groups: normoglycemic participants (group 1=27), pre-diabetes (group 2=30), and T2DM (group 3=29). Serum insulin, preptin, and myostatin levels were measured with immunoradiometric assay (IRMA), enzyme-linked immunosorbent assay (ELISA), and chemiluminescent immunoassay (CLIA), respectively. Patients with T2DM had higher levels of preptin compared to normoglycemic (461.25±53.90 vs. 407.54±54.78, P<0.001). Furthermore, these patients had elevated levels of myostatin compared with controls (2710.60±559.09 vs. 2246.37±416.40, P<0.001). Preptin and myostatin both positively correlated with serum insulin (r=0.369, P=0.01, and r=0.309, P=0.04, respectively). However, no significant association was found between serum preptin and myostatin levels. Stepwise multiple regression analysis showed that insulin was affected more by preptin, with only a trivial contribution from myostatin. Serum preptin and myostatin levels increase in prediabetic subjects and even further in type 2 diabetic patients. The correlation between preptin and insulin evolves when pre-diabetes or overt type 2 diabetes develops. Moreover, serum myostatin increases in association with insulin and not HOMA-IR in diabetic conditions.